SCHEMBL2010595

SCHEMBL2010595

Cn1cc(CC=O)c2ccccc21

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 1/20 0.65
HTR2A P28223 1/20 0.57
ALDH1A1 P00352 3/20 0.56
IMPDH2 P12268 1/20 0.56
CA2 P00918 1/20 0.53
AHR P35869 2/20 0.52
KEAP1 Q14145 1/20 0.49
NFE2L2 Q16236 1/20 0.49
KDM4E B2RXH2 3/20 0.47
LMNA P02545 2/20 0.47
GLA P06280 1/20 0.47
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CMA1 P23946 1/20 0.46
TSHR P16473 1/20 0.46
MITF O75030 1/20 0.45
MAPT P10636 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29955437 1.00 GPR84 (0.65) GPR84HTR2AALDH1A1IMPDH2CA2
SCHEMBL27613436 0.86 GPR84 (0.49) GPR84HTR2AALDH1A1IMPDH2CA2
SCHEMBL32679648 0.83 HTR2A (0.63) GPR84HTR2AALDH1A1IMPDH2CA2
SCHEMBL6943161 0.83 HTR2A (0.63) GPR84HTR2AALDH1A1IMPDH2CA2
SCHEMBL18967663 0.82 GPR84 (0.65) GPR84HTR2AALDH1A1IMPDH2CA2
SCHEMBL256689 0.81 GPR84 (0.74) GPR84HTR2AALDH1A1IMPDH2CA2
SCHEMBL21912937 0.81 HTR2A (0.65) GPR84HTR2AALDH1A1IMPDH2CA2
SCHEMBL15453266 0.80 HTR2A (0.59) GPR84HTR2AALDH1A1IMPDH2CA2
SCHEMBL20548794 0.79 GPR84 (0.71) GPR84HTR2AALDH1A1IMPDH2CA2
SCHEMBL10088110 0.79 GPR84 (0.71) GPR84HTR2AALDH1A1IMPDH2CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025072151-A1 SELECTIVE PARTIAL REDUCTION OF ESTERS USING GROUP IV TRANSITION METAL CATALYSTS AND USES THEREOF BAYLOR UNIVERSITY (US) 2025-04-03 WO disclosed
US-10815222-B2 Compounds for use in the treatment of kinetoplastid infection C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2020-10-27 US disclosed
US-20200095232-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2020-03-26 US disclosed
EP-3558980-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) 2019-10-30 EP disclosed
US-10351572-B2 Aryl hydrocarbon receptor antagonists and uses thereof Magenta Therapeutics Inc. (US) 2019-07-16 US disclosed
WO-2018115275-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION IRBM SCIENCE PARK S.P.A. (IT) 2018-06-28 WO disclosed
US-7964601-B2 Agonist or antgonist and binders and inversion of agonist PALATIN TECHNOLOGIES, INC. (US) 2011-06-21 US disclosed
US-7456184-B2 Melanocortin receptor-specific compounds PALATIN TECHNOLOGIES INC. (US) 2008-11-25 US disclosed
US-20080234289-A1 Melanocortin Receptor-Specific Compounds PALATIN TECHNOLOGIES, INC. (US) 2008-09-25 US disclosed
EP-1622618-A4 MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS PALATIN TECHNOLOGIES INC (US) 2008-08-27 EP disclosed
CN-1816337-A Naphthalene-containing melanocortin receptor-specific small molecule PALATIN TECHNOLOGIES INC (US) 2006-08-09 CN disclosed
EP-1622618-A1 MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS Palatin Technologies, Inc. (US) 2006-02-08 EP disclosed
WO-2004098602-A1 MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS PALATIN TECHNOLOGIES, INC. (US) 2004-11-18 WO disclosed
US-20040224957-A1 Melanocortin receptor-specific compounds PALATIN TECHNOLOGIES, INC. (US) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815222-B2 Compounds for use in the treatment of kinetoplastid infection NISCH, TK2, FDPS GPR84 1468/4885HTR2A 4718/4885ALDH1A1 1658/4885
US-10351572-B2 Aryl hydrocarbon receptor antagonists and uses thereof AHR, ARNT, AIPL1 GPR84 44/4885HTR2A 124/4885ALDH1A1 86/4885
US-20080234289-A1 Melanocortin Receptor-Specific Compounds MC1R, MC3R, MC5R GPR84 89/4885HTR2A 147/4885ALDH1A1 4174/4885
US-20200095232-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION NISCH, TK2, FDPS GPR84 1468/4885HTR2A 4718/4885ALDH1A1 1658/4885
US-20040224957-A1 Melanocortin receptor-specific compounds MC1R, MC5R, MC3R GPR84 120/4885HTR2A 95/4885ALDH1A1 3502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.